Alzinova
Research Alzinova (ALZ.ST) on Bullrun: market cap SEK 79.86M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALZ.ST
- ExchangeSSME
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Market capSEK 79.86M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 5.99M
- Free cash flow-SEK 21.71M
Valuation Snapshot
latest market cap is SEK 79.86M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 26.21M | -SEK 39.58M | n/a | -0.32 | SEK 319.00K | SEK 800.00K | SEK 121.96M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | SEK 79.86M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Alzinova
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alzinova's market cap?
Alzinova's market capitalization is SEK 79.86M.
What does Alzinova do?
Alzinova AB (publ), a clinical-stage biopharma company, develops immunotherapies treatment for Alzheimer's disease in Sweden. The company's lead product candidate is the ALZ-101, a therapeutic vaccine for the treatment of Alzheimer's disease, which has completed phase 1b clinical trial. It also develops ALZ-201, a monoclonal antibody that target and neutralize the neurotoxic forms of the peptide Aß42, called oligomers, which are considered to be the underlying cause of Alzheimer's disease; and a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study.